Survival of treated SCID patients. (A) Patients grouped by birth year. All treated patients, solid line (81.4%, n=93); born pre-1995, dashed/dotted line (78.6%, n=28); born 1995–1999 dashed, (75%, n=24); born in 2000 or later, with no difference pre or post 2004, dotted (87.2%, n=41). (B) Patients grouped by treatment type (includes only patients reporting a single treatment, since the order of different treatments was not available); HLA matched sibling HSCT, long-dashed line (93%, n=16); haploidentical T-depleted parent HSCT, short dashed (84%, n=50); adult matched unrelated HSCT, dotted (67%, n=9); matched unrelated cord blood, solid (67%, n=9); and PEG-ADA dashed/dotted (80%, n=5).